Putting Data Science in the Spotlight

EVERSANA team shares key clinical insights at industry leading events 

Across the pharmaceutical and life sciences industries, the need for insightful data has never been more important. 

To truly understand how data can transform patient care, many companies turn to trusted experts. Real-world data becomes meaningful only when interpreted through a clinical, scientific and epidemiological lens. Our Data & Analytics team applies deep medical expertise in disease mechanisms, treatment pathways and clinically relevant endpoints, while accounting for real-world care delivery systems and the interactions among patients, physicians and payers within specific healthcare ecosystems. This medical and scientific knowledge directs study design, methodological selection and outcome interpretation, ensuring analyses address clinically relevant questions and reflect real-world practice. 

Medical and scientific expertise directs data analysis at EVERSANA, resulting in real-world evidence that is scientifically rigorous, applicable to precision medicine and aligned with FDA expectations for real-world evidence (RWE). The resulting insights are clinically interpretable, methodologically sound and directly relevant to patient care decision-making. 

Our medical and data science experts are known as best-in-class for taking complex data sets and using scientific methodologies, producing reports that could reshape the future of care. 

In just six weeks, the team delivered eight posters across three major conferences, reinforcing EVERSANA’s position as a leader in real‑world evidence generation, advanced analytics and data‑driven healthcare insights. From gastrointestinal and metabolic diseases to oncology, cardiology, rare diseases and advanced analytics, EVERSANA’s experts highlighted how meaningful insights can shape both clinical understanding and commercialization strategy. 

Conferences presented at include: 

• Major Medical Meetings: ACG, ADA, AHA, ASCO, ASH, ATS and DDW 

• Rare Disease Conferences: WODC (USA) and WODC (Europe) 

• Scientific & Data Science Forums: ISPOR, JSM and PMSA  

Spotlight: AHA Research Gains National Media Attention 

At the American Heart Association (AHA) 2025 meeting, the team, including Dr. Pierantonio Russo, presented new findings in cardiovascular outcomes. Shortly after the event, The Cardiology Advisor published a feature highlighting several AHA studies, including work from the EVERSANA team.  

The article, “Both Early and Advanced CKD Elevate Risks for Sudden Cardiac Death, Atrial Fibrillation,” underscores the importance of analyzing clinical risk patterns across chronic kidney disease stages.
Read the story here

“Every customer that comes to EVERSANA understands just how valuable data science is to commercialization and patient care methods,” said Drew McCormick, Head of Data & Analytics. “For our team to be on the frontlines at such world-class events, showcasing results of client studies, showcases the talent we have to piece together puzzles that could change patient pathways.” 

Showcasing EVERSANA’s Expanding Capabilities 

As EVERSANA continues scaling data science, AI and real‑world evidence assets, these achievements offer a compelling snapshot of how our teams are helping reshape healthcare decision‑making. From predictive modeling to clinical risk stratification and economic evaluation, our experts are pushing boundaries across therapeutic areas and methodologies. 

Learn more about EVERSANA’s comprehensive Data & Analytics offering.